Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01230866 | Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer | active not recruiting | Phase 3 | 150 | Proton Collaborative GroupNETWORK | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02446600 | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 3 | 579 | National Cancer Institute (NCI)NIH | 4 | Sep 29, 2026 |
| clinicaltrials |
| NCT02502266 | Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer | active not recruiting | Phase 2 / Phase 3 | 582 | National Cancer Institute (NCI)NIH | 5 | Sep 29, 2026 | clinicaltrials |
| NCT02489318 | A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC(TITAN) | active not recruiting | Phase 3 | 1,052 | Aragon Pharmaceuticals, Inc.INDUSTRY | 22 | Sep 28, 2026 | clinicaltrials |
| NCT04065009 | The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer(IPLA-OVCA) | active not recruiting | Phase 3 | 220 | Karolinska InstitutetOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06331299 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer(UTOPIA) | active not recruiting | Phase 3 | 99 | UroGen Pharma Ltd.INDUSTRY | 7 | Sep 28, 2026 | clinicaltrials |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer(RAINFOL-02) | active not recruiting | Phase 3 | 584 | GenmabINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT05714202 | A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)(SunRISe-3) | active not recruiting | Phase 3 | 1,135 | Janssen Research & Development, LLCINDUSTRY | 21 | Sep 25, 2026 | clinicaltrials |
| NCT06211764 | A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)(SunRISe-5) | active not recruiting | Phase 3 | 272 | Janssen Research & Development, LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04810078 | A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread(CheckMate-67T) | active not recruiting | Phase 3 | 681 | Bristol-Myers SquibbINDUSTRY | 17 | Sep 22, 2026 | clinicaltrials |
| NCT06205316 | SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma | active not recruiting | Phase 3 | 118 | Mayo ClinicOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04579224 | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | active not recruiting | Phase 3 | 184 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05538663 | Intravesical BCG vs GEMDOCE in NMIBC(BRIDGE) | active not recruiting | Phase 3 | 870 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05863351 | Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study | active not recruiting | Phase 3 | 472 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03070886 | Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery | active not recruiting | Phase 2 / Phase 3 | 612 | NRG OncologyOTHER | 3 | Sep 14, 2026 | clinicaltrials |
| NCT06500455 | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | active not recruiting | Phase 3 | 274 | NRG OncologyOTHER | 4 | Sep 14, 2026 | clinicaltrials |
| NCT06834672 | Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | active not recruiting | Phase 3 | 450 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer(rechARge) | active not recruiting | Phase 3 | 960 | CelgeneINDUSTRY | 23 | Sep 8, 2026 | clinicaltrials |
| NCT04821622 | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | active not recruiting | Phase 3 | 599 | PfizerINDUSTRY | 27 | Sep 4, 2026 | clinicaltrials |
| NCT05704244 | Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC) | active not recruiting | Phase 3 | 25 | Ferring PharmaceuticalsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02305654 | International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)(InPACT) | active not recruiting | Phase 3 | 200 | Institute of Cancer Research, United KingdomOTHER | 2 | Aug 31, 2026 | clinicaltrials |
| NCT03793166 | Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | active not recruiting | Phase 3 | 1,175 | National Cancer Institute (NCI)NIH | 2 | Aug 31, 2026 | clinicaltrials |
| NCT01081262 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | active not recruiting | Phase 3 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT02839707 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 / Phase 3 | 444 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03055013 | Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy | active not recruiting | Phase 3 | 819 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT03244384 | Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer(AMBASSADOR) | active not recruiting | Phase 3 | 739 | National Cancer Institute (NCI)NIH | 2 | Aug 28, 2026 | clinicaltrials |
| NCT03775265 | Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer | active not recruiting | Phase 3 | 475 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT05171816 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) | active not recruiting | Phase 3 | 110 | AstraZenecaINDUSTRY | 1 | Aug 28, 2026 | clinicaltrials |
| NCT06132958 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)(TroFuse-005) | active not recruiting | Phase 3 | 710 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Aug 28, 2026 | clinicaltrials |
| NCT06459180 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | active not recruiting | Phase 3 | 686 | Merck Sharp & Dohme LLCINDUSTRY | 32 | Aug 28, 2026 | clinicaltrials |
| NCT04878094 | A Study of Intra-operative Imaging in Women With Ovarian Cancer | active not recruiting | Phase 3 | 155 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05611931 | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma(XPORT-EC-042) | active not recruiting | Phase 3 | 257 | Karyopharm Therapeutics IncINDUSTRY | 17 | Aug 27, 2026 | clinicaltrials |
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | active not recruiting | Phase 3 | 450 | National Cancer Institute (NCI)NIH | 3 | Aug 21, 2026 | clinicaltrials |
| NCT05364008 | FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea(FRIEND) | active not recruiting | Phase 3 | 33 | Yale UniversityOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT03732820 | Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 3 | 895 | AstraZenecaINDUSTRY | 17 | Aug 18, 2026 | clinicaltrials |
| NCT01407263 | Trial of Modifications to Radical Prostatectomy | active not recruiting | Phase 3 | 3,204 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04134260 | Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | active not recruiting | Phase 3 | 586 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial | active not recruiting | Phase 3 | 2,753 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05776758 | Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt | active not recruiting | Phase 3 | 236 | Regina Elena Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04736706 | A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) | active not recruiting | Phase 3 | 1,854 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Aug 14, 2026 | clinicaltrials |
| NCT06235151 | Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer(Solar-Stage) | active not recruiting | Phase 3 | 439 | Curium US LLCINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01575548 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery | active not recruiting | Phase 3 | 129 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03706365 | A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer(CYCLONE 2) | active not recruiting | Phase 2 / Phase 3 | 393 | Eli Lilly and CompanyINDUSTRY | 11 | Aug 7, 2026 | clinicaltrials |
| NCT03531099 | Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer(HIFUSA) | active not recruiting | Phase 3 | 108 | Hospices Civils de LyonOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03914612 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | active not recruiting | Phase 3 | 813 | National Cancer Institute (NCI)NIH | 5 | Jul 31, 2026 | clinicaltrials |
| NCT01874353 | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | active not recruiting | Phase 3 | 327 | AstraZenecaINDUSTRY | 17 | Jul 29, 2026 | clinicaltrials |
| NCT05678673 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma(STELLAR-304) | active not recruiting | Phase 3 | 317 | ExelixisINDUSTRY | 25 | Jul 29, 2026 | clinicaltrials |
| NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)(ASCENT-GYN-01) | active not recruiting | Phase 3 | 640 | Gilead SciencesINDUSTRY | 19 | Jul 29, 2026 | clinicaltrials |
Data updated 8 hours agoSource updated Sep 29, 2026source: clinicaltrials